# PharosBio

> PharosBio builds autonomous AI for biology. Its platform, Hydra, plans, executes, and validates real bioinformatic analysis, wrapped in a planning-and-validation layer that enforces scientific rigor. Hydra ships with ~100 scientific databases (DepMap, TCGA, cBioPortal, and more) and 200+ codified "skills" so scientists reach validated conclusions faster, without writing code or waiting weeks for a bioinformatician's report.

## What PharosBio offers

- Hydra (self-serve platform): for wet-lab scientists, PhD students, and research managers who have the data and the biological intuition but don't want to code or babysit an AI agent. Sign up and test a hypothesis now.
- Custom AI for companies: bespoke AI workflows, data & AI strategy, and development for SMB biotech and pharma teams, turning proprietary science into a self-improving competitive moat that compounds with every experiment.

## Key differentiator

Most AI research tools must be hand-steered to reach a scientific conclusion. Hydra is built for autonomous execution: it plans the analysis, executes it across ~100 preloaded databases and 200+ skills, and validates results for scientific rigor. Plans, executes, validates, not just chats.

## Key facts

- Product: Hydra, an autonomous AI platform for bioinformatics and omics analysis.
- Coverage: ~100 preloaded scientific databases, including DepMap, TCGA, and cBioPortal.
- Capabilities: 200+ codified bioinformatics "skills" (analyses the agent can plan and run end to end).
- Operating model: plans the analysis, executes it, and validates every result. Built for autonomous execution, not hand-steered chat.
- Audience: wet-lab scientists, PhD students, research managers, and SMB biotech / pharma R&D teams.
- Scale of the problem it addresses: combinatorial target spaces explode fast (two genes ≈ 200 million pairs, three ≈ 1.3 trillion), which is why automated prioritisation matters.

## Case studies

- Designing better ADCs: https://pharos.bio/case-studies/designing-adcs (which engineering levers separate clinical success from development risk: binding affinity, payload permeability, epitope, DAR)
- Combinatorial therapy: https://pharos.bio/case-studies/combinatorial-therapy (prioritising drug-combination targets when combinatorics explode: two genes ≈ 200M pairs, three ≈ 1.3 trillion)
- Safety signals in combinations: https://pharos.bio/case-studies/safety-signals-combinations (scoring which drug combinations stack toxicities and which are tolerable)
- Portfolio monitoring: https://pharos.bio/case-studies/portfolio-monitoring (continuous competitive intelligence at the speed of a question)
- Portfolio strategy: https://pharos.bio/case-studies/portfolio-strategy (turning continuous monitoring into a defensible data moat)
- Augmenting in vivo studies: https://pharos.bio/case-studies/augmenting-in-vivo (interpreting preclinical findings against human clinical outcomes and omics)
- Discovering novel targets and drug repurposing: https://pharos.bio/case-studies/discovering-novel-targets-drug-repurposing (an explainable network plus an LLM finds a novel target, EZH2, and repurposes an approved drug, tazemetostat, in HR-deficient gastric cancer)
- ADCE-T02 vs tisotumab vedotin: https://pharos.bio/case-studies/adce-t02-vs-tisotumab-vedotin (two antibody-drug conjugates against tissue factor with opposite toxicity profiles, tracing epistaxis to the Factor X exosite epitope, alopecia and neuropathy to the MMAE payload class, and the topoisomerase I interstitial lung disease risk the redesign introduces)
- AI flavor pairing for food tech: https://pharos.bio/case-studies/ai-flavor-pairing-chocolate (Hydra queries the FlavorGraph food-chemical graph to design a spicy-sweet chocolate, calibrating the similarity threshold over 43,926 compound-food pairs and finding alpha-methyl cinnamaldehyde as the one molecule bridging both flavor profiles)

## Blog

- Best AI tools for scientists in 2026: https://pharos.bio/blog/best-ai-tools-for-scientists (which AI tier fits each lab job, from general chatbots and literature AI like Elicit and Causaly to coding agents and autonomous analysis platforms, and why validated data analysis is the untapped acceleration)
- LIMS vs ELN vs SDMS vs LES: https://pharos.bio/blog/lims-vs-eln-vs-sdms-vs-les (plain-English guide to R&D lab software categories and the autonomous analysis layer emerging on top of them)
- Lab automation meets computational biology: https://pharos.bio/blog/lab-automation-computational-biology (the 8 levels of lab automation, in-house robotics vs cloud labs vs orchestration vs hit-to-lead, ten AI-native companies to watch, and how an AI reasoning layer closes the design-make-test-learn loop)
- From autocomplete to autonomous colleague: https://pharos.bio/blog/llms-in-life-sciences (eight years of language-model capability from GPT-1 and BioBERT through RAG, tool use, reasoning and autonomous agents, with what each step unlocked for biological research and what remains hard)
- Seven underused ways to use LLMs in science: https://pharos.bio/blog/llm-capabilities-science (seven judgment tasks where language models earn their keep in life science, covering scored judgments with calibration, target prioritisation by pairwise ranking, adversarial pre-submission review, scheduled landscape monitoring, systematic-review triage, run-to-run variance as uncertainty, and multi-agent panels, with prompt patterns and published evidence)
- When the cell lines are not the patients: https://pharos.bio/blog/synthetic-lethality-beyond-depmap (why cancer cell line panels under-represent myeloid patients, with one NPM1-mutant AML line for a genotype in roughly 30 percent of cases, and a three-layer approach using zero-shot language model prediction ranked against clinical cohorts rather than cultured lines)
- The EU AI Act deadline moved to 2027. What still applies now?: https://pharos.bio/blog/eu-ai-act-delay-what-still-applies (the Digital Omnibus deferred the high-risk chapter to December 2027 and August 2028 and softened the Article 4 literacy duty, but nothing currently being enforced moved, and the largest AI-related fine in Europe was issued under GDPR Article 22)
- Validating agentic AI: https://pharos.bio/blog/validating-agentic-ai (Berkeley's MAST multi-agent failure taxonomy translated into the six phases of a bioinformatics analysis, covering silent retrieval failures, strandedness and identifier errors that pass QC, threshold choices that decide results, consensus across modalities, and the human oversight of provenance that remains)
- 10 ways to use Claude for scientific work: https://pharos.bio/blog/claude-for-scientific-work (scheduled literature scans, life-science connectors like PubMed and ClinicalTrials.gov, skills and slash commands, projects, browser control, Cowork, Claude Design, Benchling integration, and Claude Code for research tooling, ending at autonomous analysis with Hydra)
- Digital transformation in pharma: https://pharos.bio/blog/agentic-ai-pharma (why most pharma AI runs as free-floating tokens instead of structured projects, the pilot-failure data from Benchling and MIT, Bain's playbook, and the radical collaboration principles that turn token burn into ROI)
- AI-native biotech in 2026: https://pharos.bio/blog/ai-native-biotech (the three-layer biology-native data stack from Bessemer's market map, AstraZeneca's three tiers of AI adoption, companies building each layer, and Hydra as the workflow automation layer)
- Identifier hell, ontology mapping in agentic drug discovery: https://pharos.bio/blog/ontology-mapping-agentic-drug-discovery (the four layers of identifier failure across genes, proteins, compounds and clinical endpoints, what the VirBench and gget virus results showed about deterministic retrieval, and where a language model belongs in an identifier pipeline)
- Will AI replace bioinformaticians: https://pharos.bio/blog/will-ai-replace-bioinformaticians (why AI absorbs pipeline work but not scientific judgement, the three transitions in the bioinformatics role, why multi-modal integration and post-hoc explainability need domain experts most, and an interpretable Reactome network that surfaced EZH2 where multiple-testing correction would bury it)
- MCP for scientific data, what a good bio server looks like: https://pharos.bio/blog/mcp-server-life-science-data (eight design rules for a Model Context Protocol server over biological data, a bad and a good tool definition compared, the failure modes that hide inside tool output, and the bio MCP servers worth connecting today including MCPmed, BioContextAI and BioinfoMCP)
- When agents disagree: https://pharos.bio/blog/when-agents-disagree (why sampling from a distribution makes some variation normal, the four causes behind answers whose logical content changes, starting with evidence the model was never trained on, why majority voting fixes one cause and destroys another, the documented biases in LLM-as-judge, adversarial refutation, and an escalation ladder from a single run to human adjudication)
- Validating AI agents under GxP: https://pharos.bio/blog/validating-ai-agents-gxp (why documented AI failures in regulated settings are oversight failures rather than stochasticity failures, and the five controls to qualify an agent as a method, after EU Annex 22 and US banking guidance SR 26-2 both put generative AI out of scope)
- Inside-out proteins, a new source of cancer surface targets: https://pharos.bio/blog/inside-out-proteins-cancer-surface-targets (two 2026 papers putting intracellular proteins on the tumour cell surface by two mechanisms, heparan sulfate tethering and autophagolysosomal exocytosis of myristoylated proteins such as Src, why the defining absence of a signal peptide makes surfaceome predictors blind to the class, and the feature stack an AI classifier would need)
- Where to put the human checkpoint in AI research: https://pharos.bio/blog/human-checkpoints-ai-research (what the evidence says about human oversight placement: a meta-analysis of 106 studies finding human plus AI often worse than the better alone, a controlled experiment where expert review reversed once ideas were executed, 70 teams reaching different conclusions from one dataset, a 90% clinical alert override rate, and four rules for where a checkpoint actually helps)
- AI-native pharmacovigilance: https://pharos.bio/blog/ai-native-pharmacovigilance (case processing is largely solved while under-reporting stays at 94 percent, and rofecoxib was visible in European health records four years before the spontaneous database flagged it)

- AI governance in pharma: https://pharos.bio/blog/ai-governance-pharma (why trust-first became governance-everywhere, the criticality matrix that tiers use cases by consequence and reach, what Moderna and Johnson and Johnson bought by releasing the low tier, and what the MD Anderson and Epic sepsis cases show the high tier is for)
- Can an AI agent take over CDMO paperwork: https://pharos.bio/blog/ai-agent-cdmo-paperwork (why the first agent on a certificate of analysis workflow should run read-only beside the coordinator, what draft Annex 22 asks about the process being replaced, the three positions an agent can occupy in the CDMO loop, and what the Telefonica O2 and Public Health England automations show about measured and unmeasured baselines)
- Vendor-agnostic AI in biopharma: https://pharos.bio/blog/vendor-agnostic-ai-biopharma (why a model router is one layer of seven, the three layers most maps leave out covering compute substrate, orchestration and oversight, how a French pharmacovigilance deployment let the shape of its data pick the model architecture, and why judging an output can cost more than producing it)
## Contact

- Website: https://pharos.bio
- Email: hello@pharos.bio
- Founders: Bogumil Zimon (CEO), Aurel Prosz (CTO)

## Usage

Content on https://pharos.bio may be quoted and cited by AI assistants and search engines. Please attribute to "PharosBio" and link to https://pharos.bio or the specific page cited.